G Gencoglan1, C Ceylan. 1. Department of Dermatology, Medical Faculty of Afyon Kocatepe University, Afyon, Turkey. gencoglan75@hotmail.com
Abstract
BACKGROUND: Cetuximab is a member of a new family of antineoplastic agents that inhibit the epidermal growth factor receptor (EGF-R), and which are increasingly being used in the treatment of solid tumors. METHODS: We have observed new secondary side effects. We present here 2 patients with acneiform eruption secondary to the administration of cetuximab (IMC-C225, Erbitux). The diagnoses of these patients were adenocarcinoma. RESULTS: Histologically, a superficial purulent folliculitis and disordered differentiation with focal parakeratosis were observed. The follicular eruption responded favorably to treatment with 5% benzoyl peroxide and 4% erythromycin gel. These lesions healed within a few days after treatment. CONCLUSION: The cutaneous adverse effects of cetuximab are similar to other EGF-R-targeted agents and result from direct interference with the functions of EGF-R signaling in the skin. (c) 2007 S. Karger AG, Basel.
BACKGROUND:Cetuximab is a member of a new family of antineoplastic agents that inhibit the epidermal growth factor receptor (EGF-R), and which are increasingly being used in the treatment of solid tumors. METHODS: We have observed new secondary side effects. We present here 2 patients with acneiform eruption secondary to the administration of cetuximab (IMC-C225, Erbitux). The diagnoses of these patients were adenocarcinoma. RESULTS: Histologically, a superficial purulent folliculitis and disordered differentiation with focal parakeratosis were observed. The follicular eruption responded favorably to treatment with 5% benzoyl peroxide and 4% erythromycin gel. These lesions healed within a few days after treatment. CONCLUSION: The cutaneous adverse effects of cetuximab are similar to other EGF-R-targeted agents and result from direct interference with the functions of EGF-R signaling in the skin. (c) 2007 S. Karger AG, Basel.
Authors: Federica Andreis; Anna Rizzi; Paola Mosconi; Claudia Braun; Luigina Rota; Fausto Meriggi; Maria Mazzocchi; Alberto Zaniboni Journal: Health Qual Life Outcomes Date: 2010-04-15 Impact factor: 3.186